Myomo, Inc. (MYO) Earnings Call Transcripts
Myomo, Inc.'s Latest Earnings Call - June 23, 2026
In Q1 2026, Myomo, Inc. reported revenue of $10.1 million, a 3% increase year-over-year, with a gross margin of 68.2%, up 100 basis points. The company is shifting its revenue model towards recurring patient sources, which now account for 49% of revenue, up from 25% a year ago. Management maintained its full-year revenue guidance of $43 million to $46 million. The stock could be influenced by the company's progress in securing payer contracts and expanding market access, as well as its efforts to improve operating leverage and reduce costs.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $10.1M (beat) |
| Gross Margin | 68.2% (beat) |
| Operating Loss | $3.2M (inline) |
| Net Loss | $3M (inline) |
| Cash and Investments | $15.7M (neutral) |
Guidance from management
Management maintained its full-year 2026 revenue guidance of $43 million to $46 million, driven by the MileConnect program and international growth.
What analysts pressed on
Analysts expressed concerns about reimbursement predictability, noting issues like payment holds and Medicare authorization denials. Management acknowledged these challenges but emphasized progress in securing payer contracts and improving authorization rates.
Main topics on the call
- Revenue Model Shift — Myomo shifted its revenue model to focus on recurring patient sources, with 49% of Q1 revenue from these sources, up from 25% a year ago. This shift aims to reduce reliance on advertising and improve scalability.
- Insurance Reimbursement — The company highlighted progress in securing Medicare and other payer contracts, covering over 100 million lives. This is expected to reduce revenue cycle friction and improve authorization rates.
- Product Development — Myomo introduced the MyoPro mobile app, reducing costs by $500 per unit. The next-generation MyoPro 3 is in development, with a potential release in late 2027 or 2028.
- Market Opportunity — Management emphasized a large addressable market, with 400,000 to 800,000 potential patients in the U.S. and 40,000 to 80,000 new patients annually. The company is the sole provider of its technology in the U.S. and Germ...
Read the full Myomo, Inc. transcript (June 23, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Myomo, Inc.
Myomo, Inc. (MYO) is a publicly listed company in the Health Care Equipment and Supplies industry, within the Health Care sector. It trades on NYSEAM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 31 calls on record spanning March 12, 2020 to August 5, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 31 Myomo, Inc. earnings call transcripts on record, spanning March 12, 2020 to August 5, 2026. Based on this history, Myomo, Inc. reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- MYO
- Exchange
- NYSEAM
- Country
- US
- Sector
- Health Care
- Calls on record
- 31
- First call
- March 12, 2020
- Most recent
- August 5, 2026
- Reporting cadence
- quarterly